+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
FEMALE
ID07415863

Phase III Study of SYS6043 Injection for Safety and Effectiveness in Adults With Advanced or Metastatic Solid Tumors

Led by CSPC Megalith Biopharmaceutical Co.,Ltd. · Updated on 2026-02-17

820

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating SYS6043, a B7-H3-targeted antibody-drug conjugate, in patients with advanced or metastatic solid tumors that have recurred or progressed after standard treatment or have no available standard therapy. This first-in-human phase III trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor effects of SYS6043. The study is sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. and includes dose escalation, PK expansion, and cohort expansion phases. Participants will receive SYS6043 as a subcutaneous injection in a non-randomized, open-label setting. The trial involves three parts dose escalation to determine the maximum tolerated dose and recommended phase 2 dose, pharmacokinetic expansion to further study the drugs behavior in the body, and cohort expansion to evaluate efficacy. Only female participants aged 18 to 75 years with some cohorts allowing older participants who meet eligibility criteria will be enrolled. During the study, participants will be monitored for adverse events and treatment responses over up to three years. Researchers will assess tumor response using objective response rate, duration of response, disease control rate, time to response, progression-free survival, and overall survival. Evaluations will include laboratory tests, imaging, biomarker analysis, and cardiac function assessments. Participants will also be followed for immune response to the drug and protein expression in tumors. Safety and tolerability will be carefully tracked throughout the trial.

CONDITIONS

Brief Title

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here